Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic follows St Jude in making V-V (ventricle-to-ventricle) upgrades for CRT (cardiac resynchronisation therapy)

This article was originally published in Clinica

Executive Summary

The US FDA has given Medtronic the all-clear to include a ventricle-to-ventricle (V-V) timing feature in its cardiac resynchronisation therapy (CRT) defibrillators for treating heart failure, making it the second firm behind St Jude Medical late last year to have gained such an approval. In addition, the agency has granted St Jude permission to make V-V timing available in all its Epic and Atlas CRT defibrillators; the feature had previously been available only in certain models of the devices.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts